Publisher
Springer International Publishing
Reference100 articles.
1. Abraham, B. K., Fritz, P., McClellan, M., Hauptvogel, P., Athelogou, M., & Brauch, H. (2005). Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clinical Cancer Research, 11(3), 1154–1159.
2. Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009). Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research, 11(4), R46. doi:
10.1186/bcr2333
.
3. Albergaria, A., Ricardo, S., Milanezi, F., Carneiro, V., Amendoeira, I., Vieira, D., … Schmitt, F. (2011). Nottingham Prognostic Index in triple-negative breast cancer: A reliable prognostic tool? BMC Cancer, 11, 299. doi:
10.1186/1471-2407-11-299
.
4. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 3983–3988. doi:
10.1073/pnas.0530291100
.
5. Ansieau, S. (2013). EMT in breast cancer stem cell generation. Cancer Letters, 338(1), 63–68. doi:
10.1016/j.canlet.2012.05.014
.